High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial [Research Articles]
This study suggests that high-throughput genomics could improve outcomes in a subset of patients with hard-to-treat cancers. Although these results are encouraging, only 7% of the successfully screened patients benefited from this approach. Randomized trials are needed to validate this hypothesis and to quantify the magnitude of benefit. Expanding drug access could increase the percentage of patients who benefit. Cancer Discov; 7(6); 586–95. ©2017 AACR.
See related commentary by Schram and Hyman, p. 552.
This article is highlighted in the In This Issue feature, p. 539 (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Authors: Massard, C., Michiels, S., Ferte, C., Le Deley, M.-C., Lacroix, L., Hollebecque, A., Verlingue, L., Ileana, E., Rosellini, S., Ammari, S., Ngo-Camus, M., Bahleda, R., Gazzah, A., Varga, A., Postel-Vinay, S., Loriot, Y., Even, C., Breuskin, I., Auger, N., Tags: Research Articles Source Type: research
An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer [Research Brief]
This article is highlighted in the In This Issue feature, p. 539 (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Authors: Hanker, A. B., Brewer, M. R., Sheehan, J. H., Koch, J. P., Sliwoski, G. R., Nagy, R., Lanman, R., Berger, M. F., Hyman, D. M., Solit, D. B., He, J., Miller, V., Cutler, R. E., Lalani, A. S., Cross, D., Lovly, C. M., Meiler, J., Arteaga, C. L. Tags: Research Brief Source Type: research
Neoadjuvant Trials in ER+ Breast Cancer: A Tool for Acceleration of Drug Development and Discovery [Reviews]
Neoadjuvant therapy trials offer an excellent strategy for drug development and discovery in breast cancer, particularly in triple-negative and HER2-overexpressing subtypes, where pathologic complete response is a good surrogate of long-term patient benefit. For estrogen receptor–positive (ER+) breast cancers, however, use of this strategy has been challenging because of the lack of validated surrogates of long-term efficacy and the overall good prognosis of the majority of patients with this cancer subtype. We review below the clinical benefits of neoadjuvant endocrine therapy for ER+/HER2-negative breast cancer, it...
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Authors: Guerrero-Zotano, A. L., Arteaga, C. L. Tags: Reviews Source Type: research
Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies [In the Spotlight]
Summary: BRAF mutations in colorectal cancer portend a poor prognosis, with first-line treatment often involving triplet or quadruplet chemotherapy, and single-agent targeted therapy with BRAF inhibitors failing to demonstrate clinical activity. Blockade of multiple critical nodes along the MAPK and other pathways may be necessary to improve response rates and survival. Cancer Discov; 7(6); 558–60. ©2017 AACR.
See related article by van Geel et al., p. 610. (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Authors: Sundar, R., Hong, D. S., Kopetz, S., Yap, T. A. Tags: In the Spotlight Source Type: research
Toward Molecularly Driven Precision Medicine in Lung Adenocarcinoma [In the Spotlight]
Summary: Assessing the benefit of routine panel-based genomic sequencing of tumor tissue remains a critical need in clinical oncology. Jordan and coauthors report on 860 patients with metastatic or recurrent lung adenocarcinoma from a single institution with prospectively sequenced tumors using a targeted gene panel of >300 genes to guide therapy. Their results suggest that early prospective tumor sequencing, including non–standard-of-care predictive biomarkers combined with careful clinical annotation, can guide therapy, improve clinical outcomes, and accelerate the development of biomarkers and drugs. Cancer Dis...
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Authors: Liu, D., Vokes, N. I., Van Allen, E. M. Tags: In the Spotlight Source Type: research
Quantifying the Benefits of Genome-Driven Oncology [In the Spotlight]
Summary: The excitement surrounding genomically selected cancer therapy has led many to question whether this treatment paradigm is living up to its initial promise. The MOSCATO study suggests that a genome-driven strategy for cancer therapy improves outcomes in a significant minority of patients who undergo molecular screening. Cancer Discov; 7(6); 552–4. ©2017 AACR.
See related article by Massard et al., p. 586. (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Authors: Schram, A. M., Hyman, D. M. Tags: In the Spotlight Source Type: research
Adoptive T-cell Therapy Has Antitumor Activity in Uveal Melanoma [Clinical Trials]
Adoptive T-cell therapy achieved responses in 35% of patients with metastatic uveal melanoma. (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Tags: Clinical Trials Source Type: research
ZEB1 Upregulates MSRB3 to Suppress Oncogene-Induced DNA Damage [Breast Cancer]
ZEB1 may block oncogene-induced DNA damage in mammary stem cells to prevent chromosomal instability. (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Tags: Breast Cancer Source Type: research
Bacterial Metabolism Alters the Efficacy of Chemotherapeutics [Chemotherapy]
Bacteria alter the response to the chemotherapeutics 5-FU, FUDR, capecitabine, and CPT in C. elegans. (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Tags: Chemotherapy Source Type: research
An Anti-CD276 Antibody-Drug Conjugate Kills Tumor Cells and Vasculature [Drug Design]
An antibody–drug conjugate linking anti-CD276 to PBD dimers has antitumor and antimetastatic activity. (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Tags: Drug Design Source Type: research
ADI-PEG 20 Depletes Arginine to Induce Antitumor Activity [Clinical Trials]
ADI-PEG 20 plus chemotherapy achieves partial responses in 7 of 9 patients with mesothelioma or NSCLC. (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Tags: Clinical Trials Source Type: research
Activation of Dectin-1 on Macrophages Promotes Pancreatic Cancer [Pancreatic Cancer]
Activation of dectin-1 on macrophages drives adaptive immune suppression and PDAC progression. (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Tags: Pancreatic Cancer Source Type: research
Type 1 T Helper Cells Promote Tumor Vessel Normalization [Angiogenesis]
TH1 cells promote tumor vessel pericyte coverage and vessel normalization to suppress metastasis. (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Tags: Angiogenesis Source Type: research
Adoptive T-cell Transfer Targets Viral and Nonviral Tumor Antigens [Immunotherapy]
Successful T-cell therapy targets nonviral tumor antigens in patients with HPV+ cervical cancer. (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Tags: Immunotherapy Source Type: research
Prolonged Stem Cell Lineage Plasticity Underlies Cancer Progression [Stem Cells]
Tumors exhibit persistent stem cell lineage plasticity that occurs transiently in wound repair. (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Tags: Stem Cells Source Type: research
